Morgan Stanley’s Mesoblast MESO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $7.91M | Sell |
514,431
-82,521
| -14% | -$1.37M | ﹤0.01% | 3770 |
|
|
2025
Q4 | $10.8M | Buy |
596,952
+131,151
| +28% | +$2.26M | ﹤0.01% | 3545 |
|
|
2025
Q3 | $7.5M | Sell |
465,801
-38,590
| -8% | -$564K | ﹤0.01% | 3804 |
|
|
2025
Q2 | $5.49M | Sell |
504,391
-40,166
| -7% | -$450K | ﹤0.01% | 3988 |
|
|
2025
Q1 | $6.8M | Buy |
544,557
+142,160
| +35% | +$2.34M | ﹤0.01% | 3664 |
|
|
2024
Q4 | $7.97M | Buy |
402,397
+228,802
| +132% | +$2.53M | ﹤0.01% | 3592 |
|
|
2024
Q3 | $1.42M | Buy |
173,595
+89,978
| +108% | +$611K | ﹤0.01% | 4844 |
|
|
2024
Q2 | $569K | Buy |
83,617
+14,715
| +21% | +$101K | ﹤0.01% | 5232 |
|
|
2024
Q1 | $345K | Sell |
68,902
-241,542
| -78% | -$514K | ﹤0.01% | 5488 |
|
|
2023
Q4 | $683K | Buy |
310,444
+265,525
| +591% | +$633K | ﹤0.01% | 5482 |
|
|
2023
Q3 | $111K | Sell |
44,919
-62,422
| -58% | -$298K | ﹤0.01% | 5852 |
|
|
2023
Q2 | $839K | Buy |
107,341
+17,316
| +19% | +$124K | ﹤0.01% | 4934 |
|
|
2023
Q1 | $592K | Sell |
90,025
-4,500
| -5% | -$29.8K | ﹤0.01% | 5152 |
|
|
2022
Q4 | $550K | Sell |
94,525
-4,089
| -4% | -$25.6K | ﹤0.01% | 5192 |
|
|
2022
Q3 | $501K | Buy |
98,614
+28,216
| +40% | +$171K | ﹤0.01% | 5266 |
|
|
2022
Q2 | $312K | Buy |
70,398
+19,377
| +38% | +$133K | ﹤0.01% | 5662 |
|
|
2022
Q1 | $431K | Sell |
51,021
-48,180
| -49% | -$410K | ﹤0.01% | 5505 |
|
|
2021
Q4 | $952K | Sell |
99,201
-7,636
| -7% | -$88.8K | ﹤0.01% | 5105 |
|
|
2021
Q3 | $1.28M | Sell |
106,837
-8,770
| -8% | -$122K | ﹤0.01% | 4886 |
|
|
2021
Q2 | $1.73M | Buy |
115,607
+89,749
| +347% | +$1.41M | ﹤0.01% | 4741 |
|
|
2021
Q1 | $428K | Buy |
25,858
+3,685
| +17% | +$69.6K | ﹤0.01% | 5240 |
|
|
2020
Q4 | $377K | Buy |
22,173
+9,475
| +75% | +$233K | ﹤0.01% | 5247 |
|
|
2020
Q3 | $472K | Buy |
12,698
+5,910
| +87% | +$185K | ﹤0.01% | 4681 |
|
|
2020
Q2 | $155K | Sell |
6,788
-30,247
| -82% | -$647K | ﹤0.01% | 5198 |
|
|
2020
Q1 | $324K | Buy |
37,035
+17,889
| +93% | +$274K | ﹤0.01% | 4621 |
|
|
2019
Q4 | $282K | Sell |
19,146
-1,324
| -6% | -$16.9K | ﹤0.01% | 5253 |
|
|
2019
Q3 | $284K | Sell |
20,470
-53,381
| -72% | -$588K | ﹤0.01% | 4958 |
|
|
2019
Q2 | $784K | Buy |
73,851
+54,647
| +285% | +$577K | ﹤0.01% | 4360 |
|
|
2019
Q1 | $201K | Sell |
19,204
-1,589
| -8% | -$14.5K | ﹤0.01% | 5062 |
|
|
2018
Q4 | $172K | Buy |
20,793
+4,180
| +25% | +$47.9K | ﹤0.01% | 5341 |
|
|
2018
Q3 | $271K | Buy |
16,613
+1,770
| +12% | +$22.5K | ﹤0.01% | 5314 |
|
|
2018
Q2 | $163K | Sell |
14,843
-2,527
| -15% | -$28.9K | ﹤0.01% | 5606 |
|
|
2018
Q1 | $201K | Buy |
17,370
+4,640
| +36% | +$55.8K | ﹤0.01% | 5462 |
|
|
2017
Q4 | $149K | Sell |
12,730
-213
| -2% | -$2.41K | ﹤0.01% | 5513 |
|
|
2017
Q3 | $142K | Buy |
12,943
+512
| +4% | +$6.87K | ﹤0.01% | 5478 |
|
|
2017
Q2 | $198K | Buy |
12,431
+1,936
| +18% | +$36.3K | ﹤0.01% | 5338 |
|
|
2017
Q1 | $189K | Buy |
10,495
+9,995
| +1,999% | +$136K | ﹤0.01% | 5344 |
|
|
2016
Q4 | $5K | Hold |
500
| – | – | ﹤0.01% | 6276 |
|
|
2016
Q3 | $4K | Hold |
500
| – | – | ﹤0.01% | 6277 |
|
|
2016
Q2 | $4K | Hold |
500
| – | – | ﹤0.01% | 6261 |
|
|
2016
Q1 | $10K | Buy |
+500
| New | +$6.86K | ﹤0.01% | 6134 |
|
Other funds holding MESO
PM
MGP
Morgan Stanley's MESO Position: Q1 2026 in Review
Morgan Stanley reduced its Mesoblast (MESO) stake by 14% in Q1 2026, selling an estimated $1.37M and leaving 514,431 shares worth $7.91M. The position accounts for ﹤0.01% of the portfolio, ranked #3770.
Morgan Stanley first reported a position in MESO in Q1 2016 and has held it in 41 quarters since. The position peaked at $10.8M in Q4 2025. 69 funds tracked by Wall St. Rank hold MESO as of Q1 2026.
- Morgan Stanley held 514,431 shares of Mesoblast worth $7.91M as of Q1 2026.
- Morgan Stanley sold 82,521 Mesoblast shares in Q1 2026, an estimated $1.37M.
- Mesoblast made up ﹤0.01% of Morgan Stanley's portfolio in Q1 2026, its #3770 holding.
- Morgan Stanley first reported a position in Mesoblast in Q1 2016 and has held it in 41 quarters since.
- Morgan Stanley's Mesoblast position peaked at $10.8M in Q4 2025.
- 69 funds tracked by Wall St. Rank held Mesoblast as of Q1 2026.
Based on Morgan Stanley's 13F filing for Q1 2026, filed 15 May 2026.